Encouraging lawmakers to pass legislation and promote policies that positively affect rheumatologists, rheumatology care teams and those living with rheumatic disease is one of the most impactful ways the ACR advances its mission. The role of advocacy has never been more critical than in recent months, when we have seen an unprecedented number of executive…
Here is a brief recap of the latest FDA-approved biosimilar agents, highlighting their reference products and interchangeability.
In response to agency requests for feedback on how to streamline regulations and reduce administrative burden on Medicare program stakeholders and small business owners, the ACR called for the removal of certain regulations related to prior authorization, pharmacy benefit managers and Medicare Part B and Part D access.
As in past administrations, members of the Executive Committee scheduled meetings with leaders of the Food & Drug Administration and Centers for Medicare & Medicaid Services to discuss ACR policy priorities and agency agendas.
Changes announced April 1 will cut 10,000 positions at the U.S. Department of Health & Human Services and consolidate many department functions. The ACR is monitoring how these changes may impact regulatory issues of concern to ACR members.
Independent, community-based rheumatologists and rheumatology professionals represent a critical part of the ACR and ARP. My immense respect for clinicians grew while watching my husband, who joined an independent practice after completing rheumatology fellowship. With admiration, I saw how he and his two dedicated partners cared for patients while simultaneously managing overhead and striving to…
The Insurance Subcommittee is working on behalf of ACR members to address underwater formulary requirements for biosimilars, mandated switches to biosimilars, evaluation and management downcoding and more.
The nominations of Jay Bhattacharya, MD, PhD, as director of the National Institutes of Health and Martin Makary, MD, MPH, for commissioner of the Food & Drug Administration have the potential to significantly impact federally funded healthcare research, federal responses to public health emergencies and federal regulation of drugs and medical devices.
In response to proposed changes to the Medicare Advantage and prescription drug programs for contract year 2026, the ACR submitted comments on the provisions related to the Inflation Reduction Act, prior authorization and the influence that pharmacy benefit managers have on the placement of biosimilars on formularies.
Dr. Feely discusses his previous work with the College, his current work as a practicing rheumatologist and how he will lead continued advances on the insurance front.